Glucagon – Like Peptide 1 (7 – 17) – Cys, GLP – 1 (7 – 17) – Cys
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | Glucagon-Like Peptide 1 (7-17)-Cys, GLP-1 (7-17)–Cys |
| CAS NO. | / |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C192H295N59O60S |
| Molecular Weight | 4421.92g/mol |
| Purity (RP-HPLC) | ≥98% |
| Solubility | Soluble in water (≥ 10 mg/mL), dilute acetic acid, and DMSO; also soluble in phosphate-buffered saline (PBS) |
| Endotoxin | ≤1.0 EU/mg |
| Biological Activity | Exhibits selective binding to GLP-1 receptors; EC₅₀ typically ≤ 2.0 nM in cAMP accumulation assays using transfected cell lines |
| Storage Conditions | tore at -20°C to -80°C in a desiccated, dark environment; avoid repeated freeze-thaw cycles. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
GLP-1 (7-17)-Cys acts primarily as a low-potency partial agonist or competitive ligand for the GLP-1 Receptor (GLP-1R). The 7-17 region contains residues critical for initial receptor engagement and activation. The peptide binds to the extracellular domain of GLP-1R with significantly lower affinity compared to full-length GLP-1, inducing minimal or sub-maximal intracellular signaling (e.g., cAMP production). Its primary utility is not for robust receptor activation but for competitive inhibition and receptor mapping.
- Receptor Binding Site Mapping: Used in competitive displacement assays to study the interaction between the GLP-1 N-terminal domain and its receptor, helping to define minimal binding epitopes.
- Molecular Probe Development: The cysteine thiol serves as a specific conjugation site for creating fluorescently labeled, biotinylated, or immobilized probes for visualizing GLP-1R (microscopy) or capturing receptor complexes (pull-down assays).
- Structure-Activity Relationship (SAR) Studies: Investigating the contribution of the N-terminal core region (residues 7-17) to GLP-1R binding and activation by comparing it to longer analogs and alanine-scanned mutants.
- Antagonist/Inhibitor Scaffold: Serving as a starting point for designing short peptide-based GLP-1R antagonists or allosteric modulators.
2.PRODUCT INDICATIONS
- Foundation for Drug Design: Research on such minimal fragments is crucial for understanding the precise molecular interactions required for GLP-1R activation. This knowledge aids in the rational design of non-peptidic small-molecule agonists, antagonists, and novel conjugates.
- Diagnostic Potential: Probes created from this fragment (e.g., fluorescent conjugates) could be used in preclinical research to image GLP-1R expression in tissues, which has implications for understanding diseases like insulinoma or obesity, but such applications are not yet clinical.
- Therapeutic Gap: This short fragment lacks the pharmacokinetic properties and potency required for a therapeutic agent. Its value is entirely in enabling basic science and technology development that may indirectly lead to future clinical innovations.
3.CLINICAL EFFICACY OF PRODUCT
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
